Clinical data | |
---|---|
Trade names | Gris-peg, Grifulvin V, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682295 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Highly variable (25 to 70%) |
Metabolism | Liver (demethylation and glucuronidation) |
Elimination half-life | 9–21 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.004.335 |
Chemical and physical data | |
Formula | C17H17ClO6 |
Molar mass | 352.77 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Griseofulvin is an antifungal medication used to treat a number of types of dermatophytoses (ringworm).[1] This includes fungal infections of the nails and scalp, as well as the skin when antifungal creams have not worked.[2] It is taken by mouth.[1]
Common side effects include allergic reactions, nausea, diarrhea, headache, trouble sleeping, and feeling tired.[1] It is not recommended in people with liver failure or porphyria.[1] Use during or in the months before pregnancy may result in harm to the baby.[1][2] Griseofulvin works by interfering with fungal mitosis.[1]
Griseofulvin was discovered in 1939 from the soil fungus Penicillium griseofulvum.[3][4][5] It is on the World Health Organization's List of Essential Medicines.[6]